<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nefr</journal-id><journal-title-group><journal-title xml:lang="ru">Нефрология</journal-title><trans-title-group xml:lang="en"><trans-title>Nephrology (Saint-Petersburg)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1561-6274</issn><issn pub-type="epub">2541-9439</issn><publisher><publisher-name>Pavlov First Saint-Petersburg State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.36485/1561-6274-2023-27-3-68-75</article-id><article-id custom-type="edn" pub-id-type="custom">HWKUHJ</article-id><article-id custom-type="elpub" pub-id-type="custom">nefr-2242</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ. КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES. CLINICAL INVESTIGATIONS</subject></subj-group></article-categories><title-group><article-title>Клиническое значение продуктов конечного гликирования и воспаления в развитии сосудистой кальцификации и кардиоваскулярных осложнений при хронической болезни почек</article-title><trans-title-group xml:lang="en"><trans-title>Clinical significance of adanced glycation end products and inflammation products in the development of vascular calcification and cardiovascular complications in chronic kidney disease</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7314-9063</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дзгоева</surname><given-names>Ф. У.</given-names></name><name name-style="western" xml:lang="en"><surname>Dzgoeva</surname><given-names>F. U.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Проф. Дзгоева Фатима Урузмаговна, д-р мед. наук, кафедра внутренних болезней №5,</p><p>362040, Республика Северная Осетия–Алания, г. Владикавказ, ул. Пушкинская, д. 40</p></bio><bio xml:lang="en"><p>Prof. Fatima U. Dzgoeva MD, PhD, DMedSci., Department of Internal Medicine №5, professor,</p><p>362040, Republic of North Ossetia-Alania, Vladikavkaz, Pushkinskaya 40</p></bio><email xlink:type="simple">fdzgoeva@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4175-5365</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ремизов</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Remizov</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Проф. Ремизов Олег Валерьевич, д-р мед. наук, кафедра лучевой диагностики с лучевой терапией и онкологией,</p><p>362040, Республика Северная Осетия–Алания, г. Владикавказ, ул. Пушкинская, д. 40</p></bio><bio xml:lang="en"><p>Prof. Oleg V. Remizov, MD, PhD, DMedSci., Department of Radiology with radiotherapy and oncology, professor,</p><p>362040, Republic of North Ossetia -Alania, Vladikavkaz, Pushkinskaya 40</p></bio><email xlink:type="simple">oleg_remizov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4183-2335</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Икоева</surname><given-names>З. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Ikoeva</surname><given-names>Z. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Икоева Зарина Руслановна, аспирант, кафедра внутренних болезней №5,</p><p>362040, Республика Северная Осетия–Алания, г. Владикавказ, ул. Пушкинская, д. 40</p></bio><bio xml:lang="en"><p>Zarina R. Ikoeva, postgraduate student, Department of Internal Medicine №5,</p><p>362040, Republic of North Ossetia-Alania, Vladikavkaz, Pushkinskaya 40</p></bio><email xlink:type="simple">zariikosha@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5310-889X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Голоева</surname><given-names>В. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Goloeva</surname><given-names>V. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Голоева Виктория Герсановна, аспирант, кафедра внутренних болезней №5,</p><p>362040, Республика Северная Осетия–Алания, г. Владикавказ, ул. Пушкинская, д. 40</p></bio><bio xml:lang="en"><p>Victoria G. Goloeva, postgraduate student, Department of Internal Medicine №5,</p><p>362040, Republic of North Ossetia-Alania, Vladikavkaz, Pushkinskaya 40</p></bio><email xlink:type="simple">vgoloeva@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-6296-9688</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гусалов</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Gusalov</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гусалов Азамат Александрович, аспирант, кафедра внутренних болезней №5,</p><p>362040, Республика Северная Осетия–Алания, г. Владикавказ, ул. Пушкинская, д. 40.</p></bio><bio xml:lang="en"><p>Azamat A.Gusalov, postgraduate student, Department of Internal Medicine №5,</p><p>362040, Republic of North Ossetia-Alania, Vladikavkaz, Pushkinskaya 40</p></bio><email xlink:type="simple">gusalov97@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Северо-Осетинская государственная медицинская академия Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>North Ossetian State Medical Academy</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>12</day><month>09</month><year>2023</year></pub-date><volume>27</volume><issue>3</issue><fpage>68</fpage><lpage>75</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Дзгоева Ф.У., Ремизов О.В., Икоева З.Р., Голоева В.Г., Гусалов А.А., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Дзгоева Ф.У., Ремизов О.В., Икоева З.Р., Голоева В.Г., Гусалов А.А.</copyright-holder><copyright-holder xml:lang="en">Dzgoeva F.U., Remizov O.V., Ikoeva Z.R., Goloeva V.G., Gusalov A.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nephrolog.ru/jour/article/view/2242">https://journal.nephrolog.ru/jour/article/view/2242</self-uri><abstract><sec><title>Введение</title><p>Введение. Кальцификация сосудов лежит в основе кардиоваскулярных осложнений, остающихся ведущей причиной высокой смертности при хронической болезни почек (ХБП). Уремическим токсинам, в том числе, продуктам конечного гликирования, отводят существенную роль в формировании этого процесса.</p></sec><sec><title>Цель исследования</title><p>Цель исследования: уточнить роль конечных продуктов гликирования и воспаления в процессах кальцификации сосудов на разных стадиях ХБП.</p></sec><sec><title>Пациенты и методы</title><p>Пациенты и методы. Обследованы 105 пациентов в возрасте от 18 до 66 лет на разных стадиях ХБП С1–С5Д, у 75 причиной которой стала диабетическая нефропатия (ДН), у 30 – иные нозологические формы. Сывороточную концентрацию конечных продуктов гликирования (AGEs), интерлейкина-6 (ИЛ-6), фактора некроза опухоли-альфа (ФНО-α), тропонина I, паратгормона (ПТГ) определяли методом иммуноферментного анализа (ИФА). Для исследования концентрации AGEs отделяли сыворотку центрифугированием (в пробирках Эппендорфа). Пробы хранили при -70 °С. Определяли индекс массы миокарда левого желудочка (ИММЛЖ). Гипертрофию левого желудочка (ГЛЖ) диагностировали при ИММЛЖ&gt;115 г/м² для мужчин и &gt;95 г/м² – для женщин. Методом дуплексного сканирования с применением эффекта Допплера исследовали пиковую систолическую скорость кровотока в дуге аорты (peak systolic velocity – Vps).</p></sec><sec><title>Результаты</title><p>Результаты. Выявлено достоверное увеличение сывороточной концентрации фосфора (р &lt; 0,05) и паратиреоидного гормона (р&lt; 0,01) по мере снижения расчетной скорости клубочковой фильтрации. Установлено увеличение концентрации AGEs, ИЛ-6 и ФНО-α на всех стадиях ХБП, наиболее выраженное на поздних стадиях – С4–С5Д (р&lt; 0,01, р&lt; 0,05, р&lt;0,05 соответственно). Выраженные изменения ИММЛЖ и Vps были связаны с высоким уровнем AGEs, ИЛ-6 и ФНО-α. ЗАКЛЮЧЕНИЕ. Повышение уровня конечных продуктов гликирования и факторов воспаления, прямо и достоверно коррелировало с тяжестью уремии и выраженностью морфофункциональных изменений сердца и аорты, что подтверждает их существенную роль в развитии сердечно-сосудистых осложнений при ХБП. Ключевые слова: конечные продукты гликирования, воспаление, кальцификация сосудов, хроническая болезнь почек &gt;˂ 0,05 соответственно). Выраженные изменения ИММЛЖ и Vps были связаны с высоким уровнем AGEs, ИЛ-6 и ФНО-α.</p></sec><sec><title>Заключение</title><p>Заключение. Повышение уровня конечных продуктов гликирования и факторов воспаления, прямо и достоверно коррелировало с тяжестью уремии и выраженностью морфофункциональных изменений сердца и аорты, что подтверждает их существенную роль в развитии сердечно-сосудистых осложнений при ХБП.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Vascular calcification underlies cardiovascular complications, which remain the leading cause of high mortality in chronic kidney disease (CKD). Uremic toxins, including the advanced glycation end products, play a significant role in the formation of this process.</p><p>The Aim of the study is to clarify the role of the advanced glycation end products (AGEs) and inflammationproducts in the processes of vascular calcification at different stages of CKD.</p></sec><sec><title>Patients and Methods</title><p>Patients and Methods. 105 patients aged 18 to 66 years at different stages of CKD C1-C5D were examined, 75 of which were caused by diabetic nephropathy (DN), 30 by other nosological forms. Serum concentrations of AGEs, IL6, TNF-α, troponin I, parathyroid hormone (PTH) were determined by enzyme immunoassay (ELISA). To study the AGEs concentration, the serum was separated by centrifugation (in Eppendorf tubes). The samples were stored at – 70 °C. The left ventricular myocardial mass index (LVMI) was determined. Left ventricular hypertrophy (LVH) was diagnosed with LVH&gt;115 g/m2 for men and &gt;95 g/m2 for women. The peak systolic velocity of blood flow in the aortic arch (Vps) was studied by duplex scanning using the Doppler effect.</p></sec><sec><title>Results</title><p>Results. A significant increase in serum phosphorus concentration (p &lt; 0.05) and PTH (p&lt; 0.01) was revealed as the glomerular filtration rate decreased. An increase in the concentration of AGEs, IL6 and TNF-α was found at all stages of CKD, most pronounced at the later stages – C4-C5D ((p&lt; 0.01, p&lt; 0.05, p&lt;0.05, respectively). Pronounced changes in LVMI and Vps were associated with high levels of AGEs, IL6 and TNF-α. CONCLUSION. An increase in the level of glycation end products and inflammatory factors directly and reliably correlated with the severity of uremia and the severity of morphofunctional changes in the heart and aorta, which confirms their significant role in the development of cardiovascular complications in CKD. Keywords: advanced glycation end products, inflammation, vascular calcification, chronic kidney disease&gt;˂0.05, respectively). Pronounced changes in LVMI and Vps were associated with high levels of AGEs, IL6 and TNF-α.</p></sec><sec><title>Conclusion</title><p>Conclusion. An increase in the level of glycation end products and inflammatory factors directly and reliably correlated with the severity of uremia and the severity of morphofunctional changes in the heart and aorta, which confirms their significant role in the development of cardiovascular complications in CKD.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>конечные продукты гликирования</kwd><kwd>воспаление</kwd><kwd>кальцификация сосудов</kwd><kwd>хроническая болезнь почек</kwd></kwd-group><kwd-group xml:lang="en"><kwd>advanced glycation end products</kwd><kwd>inflammation</kwd><kwd>vascular calcification</kwd><kwd>chronic kidney disease</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Dube P, DeRiso A, Patel M, Battepati D et al. Vascular Calcification in Chronic Kidney Disease: Diversity in the Vessel Wall. Biomedicines 2021; 9(4):404. doi.org/10.3390/biomedicines9040404</mixed-citation><mixed-citation xml:lang="en">Dube P, DeRiso A, Patel M, Battepati D et al. Vascular Calcification in Chronic Kidney Disease: Diversity in the Vessel Wall. Biomedicines 2021; 9(4):404. doi.org/10.3390/biomedicines9040404</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Koska J, Gerstein HC, Beisswenger PJ, Reaven PD. Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes. Diabetes Care 2022; 45 (3): 684–691 https://doi.org/10.2337/dc21-2196</mixed-citation><mixed-citation xml:lang="en">Koska J, Gerstein HC, Beisswenger PJ, Reaven PD. Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes. Diabetes Care 2022; 45 (3): 684–691 https://doi.org/10.2337/dc21-2196</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Perrone A, Giovino A, Benny J, Martinelli F. Advanced Glycation End Products (AGEs): Biochemistry, Signaling, Analytical Methods, and Epigenetic Effects. Oxid Med Cell Longev 2020;2020:3818196. doi:10.1155/2020/3818196</mixed-citation><mixed-citation xml:lang="en">Perrone A, Giovino A, Benny J, Martinelli F. Advanced Glycation End Products (AGEs): Biochemistry, Signaling, Analytical Methods, and Epigenetic Effects. Oxid Med Cell Longev 2020;2020:3818196. doi:10.1155/2020/3818196</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Lee J, Yun J-S, Ko S-H. Advanced Glycation End Products and Their Effect on Vascular Complications in Type 2 Diabetes Mellitus. Nutrients 2022;14(15):3086. https://doi.org/10.3390/nu14153086</mixed-citation><mixed-citation xml:lang="en">Lee J, Yun J-S, Ko S-H. Advanced Glycation End Products and Their Effect on Vascular Complications in Type 2 Diabetes Mellitus. Nutrients 2022;14(15):3086. https://doi.org/10.3390/nu14153086</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Liu Y, Wang WM, Zhang XL et al. AGE/RAGE promotes thecalcification of human aortic smooth muscle cells via the Wnt/βcatenin axis. Am J Transl Res 2016;8(11):4644–4656</mixed-citation><mixed-citation xml:lang="en">Liu Y, Wang WM, Zhang XL et al. AGE/RAGE promotes thecalcification of human aortic smooth muscle cells via the Wnt/βcatenin axis. Am J Transl Res 2016;8(11):4644–4656</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ndip A, Wilkinson FL, Jude EB et al. RANKL-OPG and RAGE modulation in vascular calcification and diabetes: novel targets for therapy. Diabetologia 2014; 57(11):2251–2260. doi: 10.1007/s00125-014-3348-z</mixed-citation><mixed-citation xml:lang="en">Ndip A, Wilkinson FL, Jude EB et al. RANKL-OPG and RAGE modulation in vascular calcification and diabetes: novel targets for therapy. Diabetologia 2014; 57(11):2251–2260. doi: 10.1007/s00125-014-3348-z</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Hénaut L, Chillon JM, Kamel S, Massy ZA. Updates on the Mechanisms and the Care of Cardiovascular Calcification in Chronic Kidney Disease. Semin Nephrol 2018;38(3):233–250. doi:10.1016/j.semnephrol.2018.02.004</mixed-citation><mixed-citation xml:lang="en">Hénaut L, Chillon JM, Kamel S, Massy ZA. Updates on the Mechanisms and the Care of Cardiovascular Calcification in Chronic Kidney Disease. Semin Nephrol 2018;38(3):233–250. doi:10.1016/j.semnephrol.2018.02.004</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Campos-Obando N, Bosman A, Kavousi M et al. Genetic Evidence for a Causal Role of Serum Phosphate in Coronary Artery Calcification: The Rotterdam Study. J Am Heart Assoc 2022;11:e023024. doi: 10.1161/JAHA.121.023024</mixed-citation><mixed-citation xml:lang="en">Campos-Obando N, Bosman A, Kavousi M et al. Genetic Evidence for a Causal Role of Serum Phosphate in Coronary Artery Calcification: The Rotterdam Study. J Am Heart Assoc 2022;11:e023024. doi: 10.1161/JAHA.121.023024</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Wang XR, Yuan L, Shi R et al. Predictors of coronary artery calcification and its association with cardiovascular events in patients with chronic kidney disease. Ren Fail 2021;43(1):1172– 1179. https://doi.org/10.1080/0886022X.2021.1953529</mixed-citation><mixed-citation xml:lang="en">Wang XR, Yuan L, Shi R et al. Predictors of coronary artery calcification and its association with cardiovascular events in patients with chronic kidney disease. Ren Fail 2021;43(1):1172– 1179. https://doi.org/10.1080/0886022X.2021.1953529</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Lee J, Yun J-S, Ko S-H. Advanced Glycation End Products and Their Effect on Vascular Complications in Type 2 Diabetes Mellitus. Nutrients 2022;14(15):3086. https://doi.org/10.3390/nu14153086</mixed-citation><mixed-citation xml:lang="en">Lee J, Yun J-S, Ko S-H. Advanced Glycation End Products and Their Effect on Vascular Complications in Type 2 Diabetes Mellitus. Nutrients 2022;14(15):3086. https://doi.org/10.3390/nu14153086</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Dozio E, Caldiroli L, Molinari P et al. Accelerated AGEing: The Impact of Advanced Glycation End Products on the Prognosis of Chronic Kidney Disease. Antioxidants 2023; 12(3):584. https://doi.org/10.3390/antiox12030584</mixed-citation><mixed-citation xml:lang="en">Dozio E, Caldiroli L, Molinari P et al. Accelerated AGEing: The Impact of Advanced Glycation End Products on the Prognosis of Chronic Kidney Disease. Antioxidants 2023; 12(3):584. https://doi.org/10.3390/antiox12030584</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kuzan A .Toxicity of advanced glycation end products. Biomed Rep 2021;14(5):1–8. doi:10.3892/br.2021.1422</mixed-citation><mixed-citation xml:lang="en">Kuzan A .Toxicity of advanced glycation end products. Biomed Rep 2021;14(5):1–8. doi:10.3892/br.2021.1422</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Martín-Carro B, Martín-Vírgala J, Fernández-Villabrille S et al. Role of Klotho and AGE/RAGE-Wnt/β-Catenin Signalling Pathway on the Development of Cardiac and Renal Fibrosis in Diabetes. Int J Mol Sci 2023;24(6):5241. https://doi.org/10.3390/ijms24065241</mixed-citation><mixed-citation xml:lang="en">Martín-Carro B, Martín-Vírgala J, Fernández-Villabrille S et al. Role of Klotho and AGE/RAGE-Wnt/β-Catenin Signalling Pathway on the Development of Cardiac and Renal Fibrosis in Diabetes. Int J Mol Sci 2023;24(6):5241. https://doi.org/10.3390/ijms24065241</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Nakano T, Kishimoto H, Tokumoto M. Direct and indirect effects of fibroblast growth factor 23 on the heart. Front Endocrinol (Lausanne) 2023;14:1059179. doi:10.3389/fendo.2023.1059179</mixed-citation><mixed-citation xml:lang="en">Nakano T, Kishimoto H, Tokumoto M. Direct and indirect effects of fibroblast growth factor 23 on the heart. Front Endocrinol (Lausanne) 2023;14:1059179. doi:10.3389/fendo.2023.1059179</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Дзгоева ФУ, Ремизов ОВ, Голоева ВГ, Икоева ЗР. Обновленные механизмы кальцификации сердечно-сосудистой системы и ее коррекции при хронической болезни почек. Нефрология 2020;24(5):18–28. https://doi.org/10.36485/1561-6274-2020-24-5-18-28</mixed-citation><mixed-citation xml:lang="en">Dzgoeva FU, Remizov OV, Goloeva VG, Ikoeva ZR. Updated mechanisms of calcification of cardiovascular system and its correction in chronic kidney disease. Nephrology (Saint-Petersburg) 2020;24(5):18–28. (In Russ.) https://doi.org/10.36485/1561-6274-2020-24-5-18-286</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Arshi B, Chen J, Ikram MA et al. Advanced Glycation End-Products, Cardiac Function and Heart Failure in the General Population: The Rotterdam Study. Diabetologia 2022;66:472–481. https://doi.org/10.1007/s00125-022-05821-3</mixed-citation><mixed-citation xml:lang="en">Arshi B, Chen J, Ikram MA et al. Advanced Glycation End-Products, Cardiac Function and Heart Failure in the General Population: The Rotterdam Study. Diabetologia 2022;66:472–481. https://doi.org/10.1007/s00125-022-05821-3</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Sabbatinelli J, Castiglione S, Macrì F et al. Circulating Levels of AGEs and Soluble RAGE Isoforms Are Associated with All-Cause Mortality and Development of Cardiovascular Complications in Type 2 Diabetes: A Retrospective Cohort Study. Cardiovasc Diabetol 2022; 21: 95. https://doi.org/10.1186/s12933-022-01535-3</mixed-citation><mixed-citation xml:lang="en">Sabbatinelli J, Castiglione S, Macrì F et al. Circulating Levels of AGEs and Soluble RAGE Isoforms Are Associated with AllCause Mortality and Development of Cardiovascular Complications in Type 2 Diabetes: A Retrospective Cohort Study. Cardiovasc Diabetol 2022; 21: 95. https://doi.org/10.1186/s12933-022-01535-3</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Zanoli L, Empana JP, Perier M-C et al. Increased carotid stiffness and remodelling at early stages of chronic kidney disease. Journal of Hypertension 2019;37(6):1176–1182. doi: 10.1097/HJH.0000000000002007</mixed-citation><mixed-citation xml:lang="en">Zanoli L, Empana JP, Perier M-C et al. Increased carotid stiffness and remodelling at early stages of chronic kidney disease. Journal of Hypertension 2019;37(6):1176–1182. doi: 10.1097/HJH.0000000000002007</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Townsend RR. Arterial Stiffness in CKD: A Review. Am J Kidney Dis 2019;73(2): 240–247. doi: 10.1053/j.ajkd.2018.04.005</mixed-citation><mixed-citation xml:lang="en">Townsend RR. Arterial Stiffness in CKD: A Review. Am J Kidney Dis 2019;73(2): 240–247. doi: 10.1053/j.ajkd.2018.04.005</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">de Faria Fonseca L, Araújo AB, da Silva Quadros KR et al. AGEs Accumulation Is Related to Muscle Degeneration and Vascular Calcification in Peritoneal Dialysis Patients. J Bras Nefrol 2021;43(2):191–199 https://doi.org/10.1590/2175-8239-JBN-2020-0119</mixed-citation><mixed-citation xml:lang="en">de Faria Fonseca L, Araújo AB, da Silva Quadros KR et al. AGEs Accumulation Is Related to Muscle Degeneration and Vascular Calcification in Peritoneal Dialysis Patients. J Bras Nefrol 2021;43(2):191–199 https://doi.org/10.1590/2175-8239-JBN-2020-0119</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Nogami M, Hoshi T, Toukairin Y et al. Immunohistochemistry of advanced glycation end product Nε -(carboxymethyl)lysine in coronary arteries in relation to cardiac fibrosis and serum N-terminal-pro basic natriuretic peptide in forensic autopsy cases. BMC Res Notes 2020;13(1):239. doi:10.1186/s13104-020-05082-6</mixed-citation><mixed-citation xml:lang="en">Nogami M, Hoshi T, Toukairin Y et al. Immunohistochemistry of advanced glycation end product Nε -(carboxymethyl)lysine in coronary arteries in relation to cardiac fibrosis and serum N-terminal-pro basic natriuretic peptide in forensic autopsy cases. BMC Res Notes 2020;13(1):239. doi:10.1186/s13104-020-05082-6</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Nakamura Y, Horii Y, Nishino T et al. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 1993;143(6):1649–1645</mixed-citation><mixed-citation xml:lang="en">Nakamura Y, Horii Y, Nishino T et al. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 1993;143(6):1649–1645</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Xu K, Zhang L, Yu N et al. Effects of advanced glycation end products (AGEs) on the differentiation potential of primary stem cells: a systematic review. Stem Cell Res Ther 2023;14(1):74. https://doi.org/10.1186/s13287-023-03324-5</mixed-citation><mixed-citation xml:lang="en">Xu K, Zhang L, Yu N et al. Effects of advanced glycation end products (AGEs) on the differentiation potential of primary stem cells: a systematic review. Stem Cell Res Ther 2023;14(1):74. https://doi.org/10.1186/s13287-023-03324-5</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
